Friday Five: The week’s top digital health news and views (18 June 2021)

We break down five of the week's most important and most read stories in healthtech.

More monitoring of aducanumab patients than prescribed? 

  • Physicians who took part in our snap survey are divided in opinion on the safety of aducanumab, the newly approved amyloid-targeting antibody for treating Alzheimer’s disease (see graph).

  • But closer monitoring of patients who will be prescribed this therapy will help assuage concerns. 

  • Some 118 neurologists and psychiatrists from the US and five major European healthcare markets took part in the survey.

To find out where other opportunities for non-pharma solutions might arise in the management of patients on aducanumab, see Physician Views Results: Monitoring tools and digital therapeutics still have a role in boosting Alzheimer’s management, post-Aduhelm.


Hims & Hers goes shopping

  • Hims & Hers, the US-headquartered specialist in virtual care services for men’s and women’s health, is acquiring Honest Health to expand into the UK and Europe.

  • Honest Health currently has a men’s hair loss service launched on its vertical healthcare platform, and plans to launch a prescription skincare service next.

  • This is Hims & Hers maiden M&A deal since it went public in January via a SPAC merger.

 

Illumina still awaiting

  • The European Commission has set a provisional deadline of July 22 to decide whether to clear Illumina's proposed acquisition of Grail. 

  • The pending $8 billion-transaction is facing opposition from antitrust authorities on both sides of the Atlantic. The US Federal Trade Commission is also taking action to stop the merger from going through.

  • Illumina has maintained the deal is pro- and not anti-competitive. 

 

Pilloxa pairs with Chiesi

  • Pilloxa will be jointly developing a tool with Chiesi Global Rare Diseases to improve medication management for patients with nephropathic cystinosis. 

  • The app, Cool 2B Rare C, is designed to provide medication reminders and increase compliance in patients with this disorder that affects the kidneys; the app is also a patient education tool. 

  • Pilloxa also has partnerships with Sandoz and Bayer.

Bet on integrated care solutions

  • Digital health companies with integrated care platforms have what it takes to succeed in the new healthcare paradigm, believes experts at Bayer G4A.

  • Companies like Cityblock Health - with their ability to scale quickly and address a person’s healthcare needs across their life journey - provide critical learnings.

  • Traditional biopharma players need to pay attention to these integrated care providers if they want to scale and win in digital health.

To get more insights from G4A’s global head, Dominick Kennerson, see Spotlight On: Where pharma should look to win in digital health

And another five:

Report says Apple's broad push into healthcare stalled as focus shifts to Watch

Wider View: Some way to go before Medtronic stands out in standalone CGM

Amalgam, Novo Nordisk to expand insulin titration app globally

Lyra Health raises $200 million to accelerate delivery of mental health benefits

Physician Views: Are opportunities for digital insomnia therapeutics awakening?

 

Did you like this article?